These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9194041)

  • 1. Genetic control of immune responses to HIV-1 env DNA vaccine.
    Ishii N; Sugita Y; Nakajima H; Bukawa H; Asakura Y; Okuda K
    Microbiol Immunol; 1997; 41(5):421-5. PubMed ID: 9194041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses.
    Liu LJ; Watabe S; Yang J; Hamajima K; Ishii N; Hagiwara E; Onari K; Xin KQ; Okuda K
    Vaccine; 2001 Oct; 20(1-2):42-8. PubMed ID: 11567744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
    Smith JM; Amara RR; McClure HM; Patel M; Sharma S; Yi H; Chennareddi L; Herndon JG; Butera ST; Heneine W; Ellenberger DL; Parekh B; Earl PL; Wyatt LS; Moss B; Robinson HL
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):654-65. PubMed ID: 15242543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of different promoters on immune responses elicited by HIV-1 gag/env multigenic DNA vaccine in Macaca mulatta and Macaca nemestrina.
    Galvin TA; Muller J; Khan AS
    Vaccine; 2000 May; 18(23):2566-83. PubMed ID: 10775791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
    Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
    Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
    Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic control of delayed-type hypersensitivity to gold antigens in mice.
    Ishii N; Takahashi K; Ishiwa M; Sugita Y; Nakajima H
    J Dermatol Sci; 1998 Jan; 16(2):104-10. PubMed ID: 9459122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery.
    Bolesta E; Kowalczyk A; Wierzbicki A; Eppolito C; Kaneko Y; Takiguchi M; Stamatatos L; Shrikant PA; Kozbor D
    J Immunol; 2006 Jul; 177(1):177-91. PubMed ID: 16785513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
    Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
    J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines.
    Kong WP; Huang Y; Yang ZY; Chakrabarti BK; Moodie Z; Nabel GJ
    J Virol; 2003 Dec; 77(23):12764-72. PubMed ID: 14610198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine.
    Tsuji T; Fukushima J; Hamajima K; Ishii N; Aoki I; Bukawa H; Ishigatsubo Y; Tani K; Okubo T; Dorf ME; Okuda K
    Immunology; 1997 Jan; 90(1):1-6. PubMed ID: 9038705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on the immunogenicity of HIV-1 gag vaccine].
    Jiang WZ; Jin NY; Li ZJ; Zhang LS
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):272-3. PubMed ID: 15193215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-HIV env immunities elicited by nucleic acid vaccines.
    Shiver JW; Davies ME; Yasutomi Y; Perry HC; Freed DC; Letvin NL; Liu MA
    Vaccine; 1997 Jun; 15(8):884-7. PubMed ID: 9234539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector.
    Shata MT; Reitz MS; DeVico AL; Lewis GK; Hone DM
    Vaccine; 2001 Nov; 20(3-4):623-9. PubMed ID: 11672930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
    Huang X; Zhu Q; Huang X; Yang L; Song Y; Zhu P; Zhou P
    Vaccine; 2017 Apr; 35(16):2042-2051. PubMed ID: 28318765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
    Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
    Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
    Guardo AC; Gómez CE; Díaz-Brito V; Pich J; Arnaiz JA; Perdiguero B; García-Arriaza J; González N; Sorzano COS; Jiménez L; Jiménez JL; Muñoz-Fernández MÁ; Gatell JM; Alcamí J; Esteban M; López Bernaldo de Quirós JC; García F; Plana M;
    PLoS One; 2017; 12(10):e0186602. PubMed ID: 29065142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.
    Jin X; Morgan C; Yu X; DeRosa S; Tomaras GD; Montefiori DC; Kublin J; Corey L; Keefer MC;
    Vaccine; 2015 May; 33(20):2347-53. PubMed ID: 25820067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeras between the human immunodeficiency virus (HIV-1) Env and vaccinia virus immunogenic proteins p14 and p39 generate in mice broadly reactive antibodies and specific activation of CD8+ T cell responses to Env.
    Collado M; Rodríguez D; Rodríguez JR; Vázquez I; Gonzalo RM; Esteban M
    Vaccine; 2000 Jul; 18(27):3123-33. PubMed ID: 10856792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.
    Khattar SK; Palaniyandi S; Samal S; LaBranche CC; Montefiori DC; Zhu X; Samal SK
    Hum Vaccin Immunother; 2015; 11(2):504-15. PubMed ID: 25695657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.